Juan Molina-Collada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Molina-Collada has a total of 360 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Castrejón
Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain; Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
11 shared publications - José María Álvaro-Gracia
Rheumatology Department, Gregorio Marañón University General Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain
11 shared publications José María Álvaro-Gracia
Hospital General Universitario Gregorio Marañón Department of Rheumatology, . , Madrid
10 shared publicationsIsabel Castrejón
Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, and Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
9 shared publications- Julia Martínez-Barrio
Hospital General Universitario Gregorio Marañón, Madrid, Spain
7 shared publications - Elisa Fernández-Fernández
Rheumatology Department, Hospital Universitario La Paz, 28046 Madrid, Spain
6 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6319
Correction: Unilateral diffuse alveolar hemorrhage in granulomatosis with polyangiitis
- 14 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6319
Open AccessCorrection: Unilateral diffuse alveolar hemorrhage in granulomatosis with polyangiitis
- Open Access
Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry
Objectives: To compare the risk of new primary cancer, locoregional progression or metastasis across different disease-modifying antirheumatic drugs (DMARDs) strategies in real-world patients with rheumatoid arthritis (RA) and prior cancer. Methods: The ARthritis and CAncer registry is a nationwide retrospective study, including patients with RA and prior cancer. Collected variables included RA characteristics, DMARDs received, cancer type and demographics. The primary outcome was the occurrence of new primary cancer, locoregional progression or metastasis during follow-up. Adjusted Cox regression models were used to estimate HRs for cancer events. Treatment strategies involving conventional synthetic (cs)DMARDs served as the reference for comparison. Results: Among 728 patients with RA, 80 cases of cancer were identified over a cumulative exposure period of 11 022 years, with an overall cancer incidence rate of 7.3 (95% CI 5.8 to 9.0) per 1000 person-years. Adjusted HRs for all cancers (95% CI) compared with csDMARDs were 0.94 (0.73 to 1.21) for tumour necrosis factor inhibitors, 1.03 (0.61 to 1.74) for IL6-inhibitors, 0.81 (0.46 to 1.42) for CD20 inhibitors, 0.6 (0.26 to 1.4) for targeted synthetic DMARDs and 0.74 (0.41 to 1.34) for cytotoxic T-lymphocyte-associated protein 4-analogue. No differences in cancer risk were observed after adjusting for duration of exposure, line of advanced therapy or prior cancer status. Conclusion: This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.
Open AccessRisk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry
Objectives: To compare the risk of new primary cancer, locoregional progression or metastasis across different disease-modifying antirheumatic drugs (DMARDs) strategies in real-world patients with rheumatoid arthritis (RA) and prior cancer. Methods: The ARthritis and CAncer registry is a nationwide retrospective study, including patients with RA and prior cancer. Collected variables included RA characteristics, DMARDs received, cancer type and demographics. The primary outcome was the occurrence of new primary cancer, locoregional progression or metastasis during follow-up. Adjusted Cox regression models were used to estimate HRs for cancer events. Treatment strategies involving conventional synthetic (cs)DMARDs served as the reference for comparison. Results: Among 728 patients with RA, 80 cases of cancer were identified over a cumulative exposure period of 11 022 years, with an overall cancer incidence rate of 7.3 (95% CI 5.8 to 9.0) per 1000 person-years. Adjusted HRs for all cancers (95% CI) compared with csDMARDs were 0.94 (0.73 to 1.21) for tumour necrosis factor inhibitors, 1.03 (0.61 to 1.74) for IL6-inhibitors, 0.81 (0.46 to 1.42) for CD20 inhibitors, 0.6 (0.26 to 1.4) for targeted synthetic DMARDs and 0.74 (0.41 to 1.34) for cytotoxic T-lymphocyte-associated protein 4-analogue. No differences in cancer risk were observed after adjusting for duration of exposure, line of advanced therapy or prior cancer status. Conclusion: This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.
- 30 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study
Objectives: To assess the prognostic value of ultrasound-based quantification of vascular inflammation for predicting relapses in giant cell arteritis (GCA). Methods: The Monitoring Activity of GCA through UltraSound (MAGiCUS) project is an international, multicentre, prospective, observational study including newly diagnosed GCA patients. Ultrasound of temporal and axillary arteries was conducted at baseline, 1, 3, 6, and 12 months. Vascular inflammation was quantified using the OMERACT GCA Ultrasonographic Score (OGUS). The primary outcome was the occurrence of the first clinical relapse between 6 and 12 months. Results: Among 156 GCA patients from 19 centres, 31 (19.9%) experienced a relapse. In patients without a relapse, OGUS was significantly lower at all follow-up visits than baseline (-0.15 to -0.35). Baseline OGUS was significantly higher in relapsing patients (1.58 vs 1.16, p < 0.001). In multivariate analysis, an increase in 0.1 units in baseline OGUS was associated with relapse (OR 1.19, 95% CI 1.08, 1.34). This association remained significant for 0.1 increases in OGUS at 1 month (OR 1.37, 95% CI 1.17, 1.66) and at 3 months (OR 1.51, 95% CI 1.20, 1.98). The areas under the receiver operating characteristic curve for predicting relapse were 0.70 (95% CI 0.58 –0.80) for baseline OGUS, 0.74 (95% CI 0.60 –0.85) at 1 month, and 0.67 (95% CI 0.56 –0.78) at 3 months. Conclusion: Ultrasound-based quantification of vascular inflammation has prognostic value for predicting relapses during follow-up in GCA. Higher baseline, 1-month and 3-months OGUS are associated with an increased probability of clinical relapse.
- 30 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study
Objectives: To assess the prognostic value of ultrasound-based quantification of vascular inflammation for predicting relapses in giant cell arteritis (GCA). Methods: The Monitoring Activity of GCA through UltraSound (MAGiCUS) project is an international, multicentre, prospective, observational study including newly diagnosed GCA patients. Ultrasound of temporal and axillary arteries was conducted at baseline, 1, 3, 6, and 12 months. Vascular inflammation was quantified using the OMERACT GCA Ultrasonographic Score (OGUS). The primary outcome was the occurrence of the first clinical relapse between 6 and 12 months. Results: Among 156 GCA patients from 19 centres, 31 (19.9%) experienced a relapse. In patients without a relapse, OGUS was significantly lower at all follow-up visits than baseline (-0.15 to -0.35). Baseline OGUS was significantly higher in relapsing patients (1.58 vs 1.16, p < 0.001). In multivariate analysis, an increase in 0.1 units in baseline OGUS was associated with relapse (OR 1.19, 95% CI 1.08, 1.34). This association remained significant for 0.1 increases in OGUS at 1 month (OR 1.37, 95% CI 1.17, 1.66) and at 3 months (OR 1.51, 95% CI 1.20, 1.98). The areas under the receiver operating characteristic curve for predicting relapse were 0.70 (95% CI 0.58 –0.80) for baseline OGUS, 0.74 (95% CI 0.60 –0.85) at 1 month, and 0.67 (95% CI 0.56 –0.78) at 3 months. Conclusion: Ultrasound-based quantification of vascular inflammation has prognostic value for predicting relapses during follow-up in GCA. Higher baseline, 1-month and 3-months OGUS are associated with an increased probability of clinical relapse.
- Open Access
- 24 April 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Ultrasound evaluation of muscle quality in rheumatoid arthritis: a reliability study of the Spanish Ultrasound Muscle Assessment in Rheumatoid Arthritis (SpUMAR) score
This study aimed to 1) develop and test the reliability of a semiquantitative ultrasound score to assess muscle quality in patients with rheumatoid arthrit
- 24 April 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessUltrasound evaluation of muscle quality in rheumatoid arthritis: a reliability study of the Spanish Ultrasound Muscle Assessment in Rheumatoid Arthritis (SpUMAR) score
This study aimed to 1) develop and test the reliability of a semiquantitative ultrasound score to assess muscle quality in patients with rheumatoid arthrit
- Open Access
- 4 February 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Dynamic vascular changes on long-term ultrasound monitoring predict relapse in large-vessel giant cell arteritis
Color duplex ultrasound (CDUS) is increasingly used to assess disease activity in large-vessel giant cell arteritis (LV-GCA), but its role in long-term mon
- 4 February 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessDynamic vascular changes on long-term ultrasound monitoring predict relapse in large-vessel giant cell arteritis
Color duplex ultrasound (CDUS) is increasingly used to assess disease activity in large-vessel giant cell arteritis (LV-GCA), but its role in long-term mon
- Open Access
- 25 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152927
Definitions and online reliability assessment of elementary ultrasound lesions in Takayasu arteritis: a study from the OMERACT Ultrasound Working Group
- 25 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152927
Open AccessDefinitions and online reliability assessment of elementary ultrasound lesions in Takayasu arteritis: a study from the OMERACT Ultrasound Working Group
- Open Access
- 7 January 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Imaging-guided stratification in giant cell arteritis: prognostic and therapeutic implications
Imaging has become a cornerstone in the clinical management of giant cell arteritis (GCA), with its role extending beyond diagnosis to include disease monitoring, risk stratification of relapse, and therapeutic decision-making. While imaging modalities have been well-established for diagnostic purposes, growing evidence supports their utility in tracking disease activity and stratifying the risk of relapse. In this narrative review, we discuss the available evidence on the prognostic and therapeutic implications of imaging-guided stratification in GCA, and highlight areas that require further research. Ultrasound assessment of intima-media thickness shows measurable improvement following treatment. While this response is relatively rapid in the cranial arteries, it occurs slowly or very slowly in extracranial vessels. Moreover, ultrasound signs and quantitative indices may be useful for distinguishing remission from relapse. Similarly, arterial inflammation assessed by 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) also improves with treatment. However, persistent large vessel vascular uptake is often observed in patients deemed to be in clinical remission. The clinical relevance of such subclinical imaging abnormalities remains unclear, underscoring the need for further research before imaging can be routinely employed for disease monitoring. Imaging may also provide valuable prognostic information. Evidence remains conflicting as to whether patients with large-vessel involvement detected by imaging may relapse more frequently, require glucocorticoid-sparing agents more often, and have an increased risk of cardiovascular events compared to those with isolated cranial GCA. However, quantifying vascular inflammation by ultrasound at diagnosis could support risk stratification and inform individualized treatment decisions. Moreover, elevated arterial uptake on 18 F-FDG PET at baseline has been associated with a higher likelihood of late vascular complications, such as aneurysm formation.
- 7 January 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Open AccessImaging-guided stratification in giant cell arteritis: prognostic and therapeutic implications
Imaging has become a cornerstone in the clinical management of giant cell arteritis (GCA), with its role extending beyond diagnosis to include disease monitoring, risk stratification of relapse, and therapeutic decision-making. While imaging modalities have been well-established for diagnostic purposes, growing evidence supports their utility in tracking disease activity and stratifying the risk of relapse. In this narrative review, we discuss the available evidence on the prognostic and therapeutic implications of imaging-guided stratification in GCA, and highlight areas that require further research. Ultrasound assessment of intima-media thickness shows measurable improvement following treatment. While this response is relatively rapid in the cranial arteries, it occurs slowly or very slowly in extracranial vessels. Moreover, ultrasound signs and quantitative indices may be useful for distinguishing remission from relapse. Similarly, arterial inflammation assessed by 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) also improves with treatment. However, persistent large vessel vascular uptake is often observed in patients deemed to be in clinical remission. The clinical relevance of such subclinical imaging abnormalities remains unclear, underscoring the need for further research before imaging can be routinely employed for disease monitoring. Imaging may also provide valuable prognostic information. Evidence remains conflicting as to whether patients with large-vessel involvement detected by imaging may relapse more frequently, require glucocorticoid-sparing agents more often, and have an increased risk of cardiovascular events compared to those with isolated cranial GCA. However, quantifying vascular inflammation by ultrasound at diagnosis could support risk stratification and inform individualized treatment decisions. Moreover, elevated arterial uptake on 18 F-FDG PET at baseline has been associated with a higher likelihood of late vascular complications, such as aneurysm formation.
- 22 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry
Objective: The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). Methods: We analysed the 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Treatment with a TNF inhibitor (TNFi) served as the reference for comparison. Results: Among 4635 of the BIOBADASER III registry patients with RA (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, the adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8–1.6) for IL6i, 0.9 (0.5–1.4) for CD20i, 1.2 (0.8–1.8) for JAKi and 1.1 (0.8–1.6) for CTLA4-A. For NMSC, the adjusted HRs (95% CI) were 0.6 (0.2–1.5) for IL6i, 0.6 (0.2–1.8) for CD20i, 0.7 (0.2–2) for JAKi, and 1.1 (0.5–2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type. Conclusion: In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi.
- 22 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry
Objective: The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). Methods: We analysed the 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Treatment with a TNF inhibitor (TNFi) served as the reference for comparison. Results: Among 4635 of the BIOBADASER III registry patients with RA (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, the adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8–1.6) for IL6i, 0.9 (0.5–1.4) for CD20i, 1.2 (0.8–1.8) for JAKi and 1.1 (0.8–1.6) for CTLA4-A. For NMSC, the adjusted HRs (95% CI) were 0.6 (0.2–1.5) for IL6i, 0.6 (0.2–1.8) for CD20i, 0.7 (0.2–2) for JAKi, and 1.1 (0.5–2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type. Conclusion: In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi.
- Open Access
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf129
Improving early referrals for inflammatory arthritis through primary care engagement: a quality improvement initiative
Objectives: Early rheumatology referral is crucial for optimal outcomes in inflammatory arthritis, but delays remain common. This quality improvement (QI) project aimed to identify barriers and implement strategies to improve referral adequacy and timeliness within a newly established early referral program. Despite the implementation of a direct referral pathway for primary care physicians, many patients did not meet eligibility criteria, limiting access for those with early inflammatory arthritis. Methods: Since January 2022, a 1 day/week early arthritis clinic has offered direct and rapid access to rheumatology appointments to 180 primary care physicians (PCPs) across 11 centres. Standardized referral criteria were co-developed with a PCPs committee. A survey assessed PCPs’ confidence, perceived barriers and educational needs using Likert scales and open-ended responses. In response to survey findings, electronic consultations (e-consults), concise referral guidelines and targeted training materials were introduced to support appropriate referrals. Results: Within the first year, the median referral time decreased from 51 to 15 days, although only 21% of referrals met the criteria. Most PCPs recognized the importance of early diagnosis (67%) but reported limited confidence in managing suspected cases (96% partially or not confident). Reported barriers included non-specific symptoms (48%) and long rheumatology wait times (39%). PCPs expressed strong interest in e-consults (87%) and brief educational tools (78%). Conclusion: This QI initiative reduced referral delays and identified key barriers to effective early arthritis referrals, including PCPs lack confidence in diagnosis and long rheumatologist wait times. Enhancing communication through e-consults and targeted educational resources may optimize early referral.
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf129
Open AccessImproving early referrals for inflammatory arthritis through primary care engagement: a quality improvement initiative
Objectives: Early rheumatology referral is crucial for optimal outcomes in inflammatory arthritis, but delays remain common. This quality improvement (QI) project aimed to identify barriers and implement strategies to improve referral adequacy and timeliness within a newly established early referral program. Despite the implementation of a direct referral pathway for primary care physicians, many patients did not meet eligibility criteria, limiting access for those with early inflammatory arthritis. Methods: Since January 2022, a 1 day/week early arthritis clinic has offered direct and rapid access to rheumatology appointments to 180 primary care physicians (PCPs) across 11 centres. Standardized referral criteria were co-developed with a PCPs committee. A survey assessed PCPs’ confidence, perceived barriers and educational needs using Likert scales and open-ended responses. In response to survey findings, electronic consultations (e-consults), concise referral guidelines and targeted training materials were introduced to support appropriate referrals. Results: Within the first year, the median referral time decreased from 51 to 15 days, although only 21% of referrals met the criteria. Most PCPs recognized the importance of early diagnosis (67%) but reported limited confidence in managing suspected cases (96% partially or not confident). Reported barriers included non-specific symptoms (48%) and long rheumatology wait times (39%). PCPs expressed strong interest in e-consults (87%) and brief educational tools (78%). Conclusion: This QI initiative reduced referral delays and identified key barriers to effective early arthritis referrals, including PCPs lack confidence in diagnosis and long rheumatologist wait times. Enhancing communication through e-consults and targeted educational resources may optimize early referral.